Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: FTSE Edges Up As Smith & Nephew And Lloyds Gain

Thu, 20th Feb 2020 08:37

(Alliance News) - The FTSE 100 was hesitantly in the green early Thursday amid ongoing caution surrounding the coronavirus outbreak, though well-received results from Smith & Nephew and Lloyds Bank were helping to lift the index.

The FTSE 100 was up 3.32 points, or 0.1%, at 7,460.34 early Thursday. The mid-cap FTSE 250 index was up 75.95 points, or 0.4%, at 21,926.81. The AIM All-Share index was up 0.3% at 975.71.

The Cboe UK 100 index was up 0.1% at 12,641.25. The Cboe 250 was up 0.4% at 19,756.90, and the Cboe Small Companies flat at 12,482.35.

In mainland Europe, the CAC 40 in Paris and DAX 30 in Frankfurt both were own 0.1% early Thursday.

"European indices have opened on a slightly softer note, backtracking from a big up day. European shares had already been pricing in the extra Chinese stimulus efforts so are looking ahead to the release of accounts of the latest ECB meeting later," said Jasper Lawler at London Capital Group.

China announced it will cut interest rates in a bid to boost the economy, as it battles the economic fallout of the new coronavirus outbreak.

The reduction in the loan prime rate – one of the preferential rates commercial banks impose on their best customers and which serves as a reference for other lending rates - is the latest measure to help companies struggling through the epidemic.

The one-year LPR was lowered to 4.05% from 4.15%, the People's Bank of China said in a statement. The five-year LPR – on which many lenders base their mortgage rates - was also lowered to 4.75% from 4.8%.

The rate reduction comes as Beijing battles to control a virus epidemic that has infected over 74,500 people in the country.

China reported a big drop in new coronavirus cases on Thursday, fuelling hopes the epidemic is nearing its peak. More than 600 new infections were reported in Wuhan, ground zero of the virus, marking the lowest daily tally since late January, and well down from the 1,749 new cases the day before.

In Tokyo on Thursday, the Nikkei 225 index ended up 0.3%. In China, the Shanghai Composite closed up 1.8%, while the Hang Seng index in Hong Kong closed down 0.2%.

At the top of London's FTSE 100 was Smith & Nephew, the stock up 6.0% after the medical technology firm reported an improved rate of underlying revenue growth for 2019.

Revenue for 2019 amounted to USD5.14 billion, up 4.8% on the year before. Underlying revenue growth was 4.4%, a significant improvement on the 2% recorded for 2018.

Pretax profit was slightly lower at USD743 million versus USD781 million the year before, hampered by increases in selling, general & administrative expenses as well as research & development costs.

The medical technology business recorded a trading profit margin of 22.8%.

For 2020, Smith & Nephew expects underlying revenue growth around 3.5% to 4.5%, which equates to a range of 4.0% to 5.0% on a reported basis. The trading profit margin for 2020 should be at or "slightly above" that achieved in 2019.

Lloyds Banking shares were up 3.1% despite the lender taking a hit to 2019 from a hefty payment protection insurance charge.

Net interest income for 2019 amounted to GBP10.18 billion, down from GBP13.40 billion in 2018.

Pretax profit was down 26% to GBP4.39 billion from GBP5.96 billion a year ago, hurt by payment protection insurance provisions of GBP2.45 billion in the year, versus just GBP750 million in 2019.

"The upside to all of this is that at least the PPI saga looks to be finally behind them, with no further provisions made in this quarter, so there's a big silver lining there," said Michael Hewson at CMC Markets.

At the bottom of the FTSE 100 was Imperial Brands, down 4.1% as the tobacco major went ex-dividend, meaning new buyers no longer qualify for the latest payout. GlaxoSmithKline, down 1.5%, also was ex-dividend.

The economic events calendar on Thursday has UK retail sales figures at 0930 GMT, followed by Irish inflation at 1100 GMT and minutes from the European Central Bank's January meeting at midday.

Ahead of the retail sales data, sterling was quoted at USD1.2888 early Thursday, down from USD1.2947 at the London equities close on Wednesday.

"Today's UK data is likely to receive a lot of attention as markets look for indications that the post-election activity pickup is continuing," said Lloyds Bank.

The euro traded at USD1.0788 early Thursday, soft against USD1.0793 late Wednesday. Against the yen, the dollar was quoted at JPY111.67, up from JPY110.93.

Brent oil was trading at USD59.02 a barrel early Thursday, up from USD58.88 late Wednesday.

Gold was quoted at USD1,609.10 an ounce early Thursday, higher than USD1,605.82 on Wednesday.

"Our best assumption is that the [gold] breakout holds and that prices move in the direction of 1650 per oz in fairly short order," said LCG's Lawler.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.